首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1736513

2026-2032 年黄热病疫苗市场（按治疗类型、最终用户和地区划分）

Yellow Fever Vaccine Market By Treatment Type (Pain Management Drugs, Oral Rehydration), By End-User (Hospitals, Point-of-Care Centers, Diagnostic Centers), & Region For 2026-2032

出版日期: 2025年05月05日 | 出版商:

Verified Market Research | 英文 | 商品交期: 2-3个工作天内

价格

简介目录

黄热病疫苗市场评估-2026-2032

国际旅行的增加，进入流行国家需要遵守疫苗接种规定，以及疫苗技术的进步提高了可及性和有效性，这些都推动了黄热病疫苗市场的发展。根据 Verified Market Research 分析师的预测，黄热病疫苗市场规模预计将在 2023 年下降约 1.4487 亿美元，并在预测期内达到 2.1864 亿美元的估值。

全球健康倡议和对黄热病威胁的认识不断提高正在推动需求，特别是随着流行地区的扩大和越来越多的旅行者寻求接种疫苗以确保人身安全，这将推动市场在 2026 年至 2032 年期间以 5.28% 的复合年增长率增长。

黄热病疫苗市场定义/概述

黄热病疫苗是一种减毒活疫苗，用于预防黄热病。黄热病是一种主要在非洲和南美洲流行的危险蚊媒疾病。单次皮下注射通常可提供终身保护，对于居住在疫区或前往疫区旅行的人来说至关重要。进入某些国家也需要接种该疫苗，这反映了其在国际旅行卫生法规中的重要性。除了个人预防外，黄热病疫苗对于疫情控制也至关重要，并为全球公共卫生工作（包括建议高风险族群进行常规疫苗接种）做出了巨大贡献。

黄热病疫苗接种的主要驱动因素是什么？

全球旅行的增加，尤其是前往黄热病流行国家的旅行，正在推动黄热病疫苗的需求。根据世界旅游组织 (UNWTO) 的数据，2019 年国际观光人数达 15 亿，其中相当一部分前往黄热病流行地区。根据美国疾病管制与预防中心 (CDC) 的数据，2019 年有近 900 万美国前往了建议或要求接种黄热病疫苗的国家。

气候变迁和都市化导致黄热病风险地区扩大，疫苗接种需求也随之增加。世界卫生组织（WHO）数据显示，2017年至2018年期间，美洲七个国家报告了确诊的黄热病病例，其中包括先前被认为无风险的地区。 2017年7月至2018年6月期间，巴西报告了1,376例确诊黄热病病例，凸显了黄热病威胁日益加剧以及疫苗接种的必要性。

此外，各国政府和国际卫生组织正在实施大规模疫苗接种计划，以预防黄热病疫情。据世界卫生组织和联合国儿童基金会称，在2016-2017年安哥拉和刚果民主共和国爆发黄热病疫情期间，紧急宣传活动为约3,000万人接种了疫苗。此外，世界卫生组织的「终结黄热病」（EYE）倡议旨在到2026年为10亿人接种疫苗，这将增加对黄热病疫苗的需求。

哪些挑战阻碍了黄热病疫苗市场的成长？

黄热病疫苗的潜在副作用是市场成长的主要障碍。常见的副作用包括头痛、肌肉疼痛和疲劳，这些副作用会阻碍人们接种疫苗。对这些副作用的担忧导致疫苗需求下降，尤其是在那些对疫苗接种持谨慎态度的人群中。这种犹豫降低了旨在控制黄热病发生的疫苗接种的整体有效性。

此外，基础设施瓶颈也对市场产生了重大影响。疫苗必须透过先进的低温运输物流配送，才能在运输和储存过程中保持其有效性。在许多黄热病流行地区，有限的医疗设施和物流瓶颈阻碍了及时的疫苗接种工作。这些限制因素限制了弱势族群获得疫苗的机会，从而阻碍了预防黄热病传播的努力，最终影响了市场成长。

The rising international travel, which requires vaccination compliance for admission into endemic countries, and technological developments in vaccines that improve accessibility and efficacy are driving the Yellow Fever Vaccine Market. According to the analyst from Verified Market Research, the Yellow Fever Vaccine Market is estimated to reach a valuation of USD 218.64 Million over the forecast subjugating around USD 144.87 Million in 2023.

The global health initiatives and increased knowledge of yellow fever threats are driving up demand, especially as endemic zones grow and more travelers seek inoculation for personal safety. It enables the market to grow at a CAGR of 5.28% from 2026 to 2032.

Yellow Fever Vaccine Market: Definition/ Overview

The yellow fever vaccine is a live, attenuated virus vaccine used to prevent yellow fever, a dangerous disease spread mostly by mosquitos in Africa and South America. When given as a single subcutaneous dose, it often gives lifelong protection, making it critical for anyone living in or going to endemic areas. The vaccine is also necessary for entry into certain countries, demonstrating its importance in international travel health rules. The yellow fever vaccine has applications beyond individual protection; it is critical in outbreak control and is recommended for routine immunization in at-risk populations, considerably contributing to worldwide public health initiatives.

What are the Key Drivers that Foster the Adoption of Yellow Fever Vaccines?

The increase in worldwide travel, particularly to yellow fever-endemic countries, is driving up demand for yellow fever vaccines. According to the World Tourism Organization (UNWTO), international tourist arrivals totaled 1.5 billion in 2019, with a sizable proportion of these visitors traveling to areas where yellow fever is prevalent. According to the Centers for Disease Control and Prevention (CDC), nearly 9 million Americans visited countries where yellow fever vaccination is recommended or necessary in 2019.

Climate change and urbanization are contributing to the spread of yellow fever risk areas, increasing the demand for vaccination. According to the World Health Organization (WHO), seven nations in the Americas reported verified yellow fever cases between 2017 and 2018, including areas that were previously considered risk-free. Between July 2017 and June 2018, 1,376 confirmed cases of yellow fever were reported in Brazil, underscoring the growing threat and need for vaccinations.

Furthermore, governments and international health organizations are putting in place large-scale vaccination programs to prevent yellow fever epidemics. According to WHO and UNICEF, almost 30 million people were vaccinated in emergency campaigns during the yellow fever outbreaks in Angola and the Democratic Republic of the Congo in 2016-2017. Also, the WHO's Eliminate Yellow Fever Epidemics (EYE) initiative seeks to vaccinate 1 billion people by 2026, increasing demand for yellow fever vaccines.

What are the Challenges Hindering the Growth of the Yellow Fever Vaccine Market?

The potential negative effects of the yellow fever vaccine are a substantial barrier to market growth. Common adverse responses include headaches, muscle soreness, and exhaustion, which discourage people from getting vaccinated. Concerns about these side effects contribute to decreased demand, particularly among people who are already wary of immunizations. This hesitation reduces the overall effectiveness of vaccination initiatives aimed at limiting yellow fever outbreaks.

Furthermore, infrastructure bottlenecks have a big impact on the market. To preserve efficacy during shipping and storage, vaccinations must be distributed via sophisticated cold-chain logistics. In many endemic areas, limited healthcare facilities and logistical obstacles prevent timely immunization efforts. These constraints restrict vulnerable groups' access to vaccines, ultimately hampering attempts to prevent the spread of yellow fever and affecting market growth.

Category-Wise Acumens

What Factors Contribute to the Market Leadership of Oral Rehydration Treatment?

According to VMR analysis, the oral rehydration segment is estimated to hold the largest market share during the forecast period due to the high prevalence of dehydration associated with yellow fever, which demands rapid rehydration therapy as the first line of treatment. Oral rehydration treatments are effective in replacing lost fluids and electrolytes, making them necessary for patient recovery. This acute requirement for hydration promotes the demand for oral rehydration solutions in the market.

Health agencies such as the World Health Organization (WHO) and UNICEF strongly support oral rehydration as a critical treatment for yellow fever-induced dehydration, which is a further major concern. Their campaign not only promotes awareness but also inspires healthcare providers to prioritize oral rehydration products, resulting in increased market growth and acceptance by patients.

Furthermore, the growing availability and diversity of oral rehydration products help to maintain the segment's dominance. Formulation innovations like flavored liquids and effervescent tablets improve patient compliance and happiness. As these medications become more widely available through multiple distribution channels, they strengthen their position as the primary treatment for yellow fever-related dehydration.

What are the Key Driving Forces for the Yellow Fever Vaccines in Hospitals?

The hospital segment is estimated to dominate the Yellow Fever Vaccine Market during the forecast period due to the increasing dominance is increased vaccination awareness among visitors and local populations in endemic areas. Hospitals are key healthcare providers where people get immunizations, especially before going to locations where yellow fever is common. This increased knowledge results in an increase in hospital visits for immunizations, cementing their segment position.

The provision of comprehensive healthcare services in hospitals is a further significant factor driving the segment. These facilities not only provide vaccines but also offer pre-vaccination consultations and post-vaccination care, boosting patient trust and encouraging more people to get immunized. This integrated approach leads to higher immunization rates than in other contexts.

Furthermore, government initiatives and health programs focused on limiting yellow fever outbreaks prioritize hospital vaccination campaigns. Collaboration between hospitals and public health agencies ensures that vaccines are easily available, particularly during outbreaks or high travel seasons, bolstering hospitals' market position.

Country/Region-wise Acumens

What Drivers Contribute to the Sustained Dominance of North America in this Market?

According to VMR analyst, North America is estimated to dominate the Yellow Fever Vaccine Market during the forecast period. North America, particularly the United States, has a large number of international visitors to yellow fever endemic areas. According to the National Travel and Tourism Office of the United States Department of Commerce, 93.0 million Americans left the country for overseas travel in 2018 alone. According to the Centers for Disease Control and Prevention (CDC), nearly 9 million Americans visited countries where yellow fever vaccination is recommended or necessary in 2019. The increasing number of visitors to high-risk areas fuels the demand for yellow fever vaccines in the North American market.

Furthermore, North America, particularly the United States and Canada, has a well-developed healthcare and vaccination infrastructure. The CDC's Advisory Committee on Immunization Practices (ACIP) advises yellow fever immunization for visitors to endemic countries. In 2019, the CDC estimated that there were over 4,500 yellow fever vaccination clinics in the United States, ensuring extensive availability of the vaccine. This broad network of vaccination centers contributes to the region's dominant position in the Yellow Fever Vaccine Market.

What are the Factors Leading to Substantial Growth of the Market in Europe?

Europe region is estimated to exhibit substantial growth within the market during the forecast period. International travel in Europe has increased significantly, particularly to regions where yellow fever is widespread. According to the European Travel Commission, European outward travel grew by 7% in 2019, totaling 1.1 billion trips. The European Centre for Disease Prevention and Control (ECDC) reported 13 travel-associated yellow fever cases among European visitors between 2012 and 2018, emphasizing the importance of vaccination for European tourists visiting endemic locations. This expanding trend in foreign travel is a significant driver of the Yellow Fever Vaccine Market in Europe.

Furthermore, strong immunization and public health initiatives have been put in place by European nations to safeguard tourists. According to the World Health Organization's (WHO) European Region, there were over 7,000 authorized yellow fever vaccination facilities throughout Europe in 2019. According to France's National Public Health Agency, the number of yellow fever vaccination doses administered climbed from 169,000 in 2015 to 194,000 in 2019. The broad availability and use of yellow fever vaccinations help to drive market expansion in Europe.

Competitive Landscape

The competitive landscape of the Yellow Fever Vaccine Market is characterized by a dynamic interaction of innovation, regulatory compliance, and strategic alliances. As the demand for yellow fever immunization rises due to increased international travel and health advisories, stakeholders are working on improving vaccine efficacy and accessibility through advanced R&D projects.

Some of the prominent players operating in the Yellow Fever Vaccine Market include:

Takeda Pharmaceutical Company Ltd, Merck & Co, Inc., GlaxoSmithKline PLC, Biological E Limited, Panacea Biotec, iBio, Inc., FSUE Chumakov, Institut Pasteur de Dakar, Bio Manguinhos, and Sanofi Pasteur SA.

Latest Developments

In April 2021, Sanofi Pasteur announced that YF-VAX is now available for purchase in the United States. YF-VAX can now be ordered from the manufacturer by providers who have a current Yellow Fever Vaccination Stamp from their state or territory health department.

1 INTRODUCTION OF GLOBAL YELLOW FEVER VACCINE MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL YELLOW FEVER VACCINE MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL YELLOW FEVER VACCINE MARKET, BY TREATMENT TYPE

5.1 Overview
5.2 Pain Management Drugs
5.3 Oral Rehydration

6 GLOBAL YELLOW FEVER VACCINE MARKET, BY END USER

6.1 Overview
6.2 Hospitals
6.3 Diagnostic Centers
6.4 Point of Care Centers
6.5 Others

7 GLOBAL YELLOW FEVER VACCINE MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East & Africa

8 GLOBAL YELLOW FEVER VACCINE MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 Takeda Pharmaceutical Company Ltd
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 Merck & Co Inc
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 GlaxoSmithKline PLC
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 Biological E Limited
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 Panacea Biotec
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 iBio Inc
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
9.7 FSUE Chumakov
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments
9.8 Institut Pasteur de Dakar
- 9.8.1 Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Outlook
- 9.8.4 Key Developments
9.9 Bio Manguinhos
- 9.9.1 Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Outlook
- 9.9.4 Key Developments
9.10 Sanofi Pasteur SA
- 9.10.1 Overview
- 9.10.2 Financial Performance
- 9.10.3 Product Outlook
- 9.10.4 Key Developments

10 KEY DEVELOPMENTS

10.1 Product Launches/Developments
10.2 Mergers and Acquisitions
10.3 Business Expansions
10.4 Partnerships and Collaborations

11 Appendix

11.1 Related Research

02-2729-4219

+886-2-2729-4219

License/价格

2026-2032 年黄热病疫苗市场（按治疗类型、最终用户和地区划分）

Yellow Fever Vaccine Market By Treatment Type (Pain Management Drugs, Oral Rehydration), By End-User (Hospitals, Point-of-Care Centers, Diagnostic Centers), & Region For 2026-2032

黄热病疫苗市场评估-2026-2032

黄热病疫苗接种的主要驱动因素是什么？

哪些挑战阻碍了黄热病疫苗市场的成长？

目录

第一章 黄热病疫苗全球市场介绍

第二章执行摘要

第三章：已验证的市场研究调查方法

第四章全球黄热病疫苗市场展望

5. 全球黄热病疫苗市场（依治疗类型）

6. 全球黄热病疫苗市场（依最终用户）

7. 全球黄热病疫苗市场（按地区）

8. 全球黄热病疫苗市场的竞争格局

第九章 公司简介

第十章 重大进展

第十一章 附录

Yellow Fever Vaccine Market Valuation - 2026-2032